Compare BRAI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRAI | RCUS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | N/A | 2018 |
| Metric | BRAI | RCUS |
|---|---|---|
| Price | $12.49 | $25.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $31.90 |
| AVG Volume (30 Days) | 494.7K | ★ 788.7K |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $45.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.62 | $7.92 |
| 52 Week High | $32.32 | $28.72 |
| Indicator | BRAI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 57.35 |
| Support Level | $12.56 | $23.91 |
| Resistance Level | $27.42 | $26.70 |
| Average True Range (ATR) | 1.82 | 1.10 |
| MACD | 1.19 | -0.02 |
| Stochastic Oscillator | 49.45 | 84.53 |
Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.